YH32364

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR Overexpression

Conditions

EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor

Trial Timeline

Jun 12, 2025 → Dec 1, 2029

NCT ID

NCT06975410

About YH32364

YH32364 is a phase 1/2 stage product being developed by Yuhan for EGFR Overexpression. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06975410. Target conditions include EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor.

What happened to similar drugs?

1 of 7 similar drugs in EGFR Overexpression were approved

Approved (1) Terminated (1) Active (5)

✅GefitinibAstraZenecaApproved

🔄AZD9291 + MEDI4736AstraZenecaPhase 3

🔄AZD9291 80mg oral each dayAstraZenecaPhase 3

🔄AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mgAstraZenecaPhase 3

🔄Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3

❌ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLYRochePhase 3

🔄Dacomitinib (PF-00299804) + GefitinibPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06975410	Phase 1/2	Recruiting	Jun 12, 2025	Dec 1, 2029	EGFR Overexpression

Competing Products

20 competing products in EGFR Overexpression

See all competitors

Product	Company	Stage	Hype Score
YH25448	Yuhan	Phase 1/2	32
Datopotamab deruxtecan	Daiichi Sankyo	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
ASP8273	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
erlotinib	Astellas Pharma	Phase 1	29
ASP8273 Capsules + ASP8273 Capsules A	Astellas Pharma	Phase 2	27
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	31
ABT-414	AbbVie	Pre-clinical	26
AZD9291 40 mg + AZD9291 80 mg	AstraZeneca	Phase 1	29
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	42
AZD9291 + MEDI4736	AstraZeneca	Phase 3	40
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)	AstraZeneca	Pre-clinical	22
AZD9291	AstraZeneca	Pre-clinical	26
Osimertinib	AstraZeneca	Phase 2	35
Dasatinib + Osimertinib	AstraZeneca	Phase 1/2	24
AZD9291 80mg oral each day	AstraZeneca	Phase 3	36
Tremelimumab + Durvalumab	AstraZeneca	Phase 2	31
Osimertinib	AstraZeneca	Phase 2	35
AZD3759 + AZD9291	AstraZeneca	Phase 1	29